First Anti-TNF Infusion Therapy Approved in More Than a Decade for Patients Living with Moderately to Severely Active Rheumatoid Arthritis "Phase 3 data showed treatment with SIMPONI ARIA plus ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Janssen Biotech announced new five-year data from three pivotal Phase 3 studies evaluating Simponi (golimumab) 50mg administered subcutaneously once every four weeks in the treatment of moderately to ...

HORSHAM, Pa., Sept. 30, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA ® ...

New Phase 3 study findings show that subcutaneous induction regimens of Simponi (golimumab; Janssen Biotech, Inc.) induced clinical response in a majority of patients with moderately to severely ...

LEIDEN, Netherlands, May 27, 2016 /PRNewswire/ -- Janssen Biologics B.V. (Janssen) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...

Please provide your email address to receive an email when new articles are posted on . Janssen Biotech announced that the FDA has expanded the labeling provisions for Simponi Aria infusions in ...

Sometimes follow-on drugs are flubs that would have been better put in the trash can, but I don't think that'll be the case for Johnson & Johnson's (NYSE:JNJ) Simponi: it was approved on Friday for ...

Remicade (infliximab), a biologic drug for the treatment of rheumatoid arthritis and other autoimmune diseases, remains the top growth driver for Johnson & Johnson (JNJ). Positioning two new ...